TY  - JOUR
AU  - Hernández-Cruz, Blanca
AU  - Márquez-Saavedra, Esther
AU  - Caliz-Caliz, Rafael
AU  - Navarro-Sarabia, Federico
PY  - 2016
DO  - 10.1186/s13075-016-1137-4
SN  - 1478-6354
UR  - http://hdl.handle.net/10668/2538
T2  - Arthritis Research & Therapy
AB  - BACKGROUNDRheumatoid arthritis (RA) patients are treated with a mean of 3-4 conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) with or without glucocorticoids (GCs), before the first biologic prescription. The main reasons for...
LA  - en
PB  - BioMed Central
KW  - Glucocorticoids
KW  - RA
KW  - TNF antagonist
KW  - csDMARDs
KW  - Artritis reumatoide
KW  - Antirreumáticos
KW  - Factores biológicos
KW  - Glucocorticoides
KW  - Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antirheumatic Agents
KW  - Medical Subject Headings::Diseases::Musculoskeletal Diseases::Joint Diseases::Arthritis::Arthritis, Rheumatoid
KW  - Medical Subject Headings::Chemicals and Drugs::Biological Factors
KW  - Medical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Comorbidity
KW  - Medical Subject Headings::Check Tags::Female
KW  - Medical Subject Headings::Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones::Glucocorticoids
KW  - Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
KW  - Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienediols::Prednisone
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal...
KW  - Medical Subject Headings::Chemicals and Drugs::Complex Mixtures::Biological Products
TI  - Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
TY  - research article
ER  -